



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
NOESKE-JUNGBLUT et al. : Group Art Unit.: 1653
Serial No.: 10/694,847 : Examiner: SNEDDEN, Sheridan
Filed: October 29, 2003 : Docket No.: KOENIG-2D1

Title: THROMBIN INHIBITING PEPTIDE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY


Sir:

In response to the Office Action mailed on October 4, 2004, applicants elect with traverse group I for further prosecution and elect the following peptide: Lys-Ile-Ser-Val-Ser-Tyr-Asp-Asn-Phe-Ala-Leu-Val-Asp-Tyr-Leu-Val-Phe-Glu-Arg-Thr-Lys-Ser-Asp-Thr-Asp.

The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Csaba Henter, Reg. No. 50,908
Anthony J. Zelano, Reg. No. 27,969
Attorneys for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: April 1, 2005

K:\koenig\2D1\Reply Apr 05.doc